Translation regulation—the process by which the amount of protein synthesized from its messenger RNA (mRNA) is controlled—is a crucial step in establishing the degree of gene expression during events such as cell proliferation, differentiation, development, nervous system function, as well as in diseases like cancer. Compared to transcriptional regulation, the translational control of existing mRNAs­—RNAs are the molecules that carry genetic information for protein synthesis—allows a faster response to stimuli.

The journal Nature Structural & Molecular Biology has published a study on the regulation of mRNA translation by researchers in the Translational Control of Cell Cycle and Differentiation Laboratory at the Institute for Research in Biomedicine (IRB Barcelona). Headed by ICREA Research Professor Raúl Méndez, an expert on the CPEB (cytoplasmic polyadenylation element binding protein) protein family, this study reveals the interplay between the proteins CPEB1 and Musashi1 (Msi1) in the regulation of mRNA translation.

The CPEB family of proteins is responsible for the translational control of maternal mRNAs by a process called “cytoplasmic polyadenylation”. “In this study our aim has been to determine whether Msi1 and CPEB1 act cooperatively to regulate mRNA polyadenylation,” explains Eulàlia Belloc, co-first author of the study and associate researcher with Méndez’s Laboratory.

In the study, researchers have identified that “even though polyadenylation of a CPE-containing mRNAs relies on CPEB1, for c-mos, net1 and probably other mRNAs, a nearby Msi1 binding site is required to remodel the RNA secondary structure so that the CPE becomes accessible,” Belloc explains.

Through a genome-wide analysis of CPEB1- and Msi1-associated mRNAs in the frog Xenopus laevis model, the scientists have identified 491 common targets, thus revealing a new layer of CPE-mediated translational control. “We have estimated that more mRNAs could also be co-regulated by CPEB1 and Msi1,” comments the researcher.

A combinatorial code

“Several years ago our lab defined a combinatorial code where the number and distance of the CPEB binding element (CPE) to the PAS (polyadenylation signal), as well as the presence of additional cis-acting elements, determine the transcript-specific spatiotemporal pattern of translation,” explains Eulàlia. The findings described in this work now deepen our knowledge of the combinatorial code, allowing us to better understand diseases such as cancer—a process in which this translational regulation is altered.

This study has received funding from the Fundación Botín and the Banco Santander (through its Santander Universities Global Division), the Asociación Española Contra el Cáncer (AECC) (Spanish Association Against Cancer), the Worldwide Cancer Research, MINECO (Spanish Ministry of Economy, Industry and Competitiveness) and ERDFs.

Reference article:

Laure Weill, Eulàlia Belloc, Chiara Lara Castellazzi and Raúl Méndez.

Musashi 1 regulates the timing and extent of meiotic mRNA translational activation by promoting the use of specific CPEs

Nature Structural and Molecular Biology (2017)

(Written by: Llúcia Ribot)

Image: The experiments have been carried out using Xenopus laevis oocytes, an animal model used by the laboratory to study fundamental processes involved in gene regulation. Image: microscopy, Eulàlia Belloc.

Fuente: Instituto de Investigación Biomédica ( IRB Barcelona )

https://www.irbbarcelona.org/es/news/hacia-una-comprension-mas-profunda-de-la-regulacion-del-genoma
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream